Overview

Detailed Summary

Transgene Biotek Ltd, founded in 1990, is a pioneering biotechnology company in India, focusing on research and development of vaccines, oncology products, and new drug delivery technologies.
The company has a robust product export portfolio, reaching markets in Africa, Russia, China, Malaysia, and the Philippines.
A significant development includes the planned setup of a manufacturing facility at Anrich Industrial Area with a Rs. 30 crore investment, supported by preferential offer funding from Batterymarch Financial Management USA and other financial institutions.
Transgene is advancing in novel delivery systems for proteins, peptides, and biologicals, with a particular emphasis on oral and nasal formulations.
The company targets novel therapies in oncology and auto-immune diseases, addressing vital areas of unmet medical need.

Sector: Healthcare Services
Industry: Healthcare Service Provider
Market Cap: 24 Cr
Volatility: High Risk
P/E Ratio: -12.6
Industry P/E: 60.1
PEG Ratio: —
P/B Ratio: 2.5
52W High: 5.26
52W Low: 1.83

Sales CAGR

1Y: 13.04%
3Y: 44.34%
5Y: 135.81%
10Y: 4.10%

Profit CAGR

1Y: -3.03%
3Y: —
5Y: —
10Y: —

ROE

TTM: -17.64%
3Y: -22.86%
5Y: -39.28%
10Y: -22.08%

ROCE

TTM: -3.52%
3Y: -1.72%
5Y: -4.02%
10Y: -5.55%

Technicals

‌

Forecasts

Peers

Healthcare Healthcare Healthcare Services Healthcare Service Provider

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
SHARMEH		104.00	34 Cr	28.39	2.76	0.00	9.84	10.99	3.78
DECCAN		12.67	32 Cr	14.09	0.29	0.00	1.30	1.99	1.64
CMMHOSP		35.75	29 Cr	-35.16	0.00	0.00	35.31	-0.76	-3.69
TEJNAKSH		15.44	28 Cr	20.73	1.07	0.00	6.34	9.29	4.08
TRABI		3.20	23 Cr	-12.32	2.54	0.00	-17.64	-3.52	-1.32
NIDAN		14.00	20 Cr	8.67	0.29	0.00	3.32	6.57	2.69
FAMILYCARE		3.22	17 Cr	-1.93	1.78	0.00	-46.60	-27.58	-20.17
Median: 7 Co.	—	14.00	28 Cr	8.67	1.07	0.00	3.32	1.99	1.64

Financial Statements

Upcoming Result Date: May 28, 2026

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	0.05	0.05	0.05	0.05	0.06	0.08	0.08	0.05	0.05	0.05
Expenses	0.17	0.16	0.32	0.46	0.14	0.17	0.62	0.19	0.13	0.10
Operating Profit	-0.12	-0.11	-0.27	-0.41	-0.08	-0.09	-0.54	-0.14	-0.08	-0.05
OPM %	-240.00	-220.00	-540.00	-820.00	-133.33	-112.50	-675.00	-280.00	-160.00	-100.00
Other Income	0.04	0.04	0.05	0.65	0.04	0.04	0.04	0.00	0.00	0.00
Interest	0.03	0.03	0.03	0.02	0.02	0.02	0.19	0.25	0.26	0.27
Depreciation	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.05	0.05	0.05
Profit Before Tax	-0.13	-0.12	-0.27	0.20	-0.07	-0.09	-0.71	-0.43	-0.39	-0.37
Tax %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit	-0.13	-0.12	-0.27	0.20	-0.07	-0.09	-0.71	-0.43	-0.39	-0.37
EPS in Rs	-0.02	-0.02	-0.04	0.03	-0.01	-0.01	-0.09	-0.06	-0.05	-0.05

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	0.28	0.12	0.07	0.00	0.17	0.09	0.06	0.23	—	0.27
Expenses	2.84	2.22	0.76	0.87	0.70	0.55	1.11	0.85	0.00	1.12
Operating Profit	-2.56	-2.11	-0.69	-0.86	-0.53	-0.46	-1.05	-0.62	0.00	-0.85
OPM %	-911.91	-1,780.70	-961.81	-24,155.77	-310.98	-534.52	-1,910.16	-262.58	—	-314.81
Other Income	0.66	7.37	2.04	0.18	0.27	0.21	0.18	0.18	0.00	NaN
Interest	0.43	1.03	0.25	0.38	0.27	0.23	0.18	0.13	—	0.48
Depreciation	18	9.89	9.89	9.90	9.91	9.92	4.95	0.09	—	0.11
Profit Before Tax	-20	-5.65	-8.79	-11	-10	-10	-6.01	-0.66	—	-1.30
Tax %	0.00	-13.91	0.00	0.00	0.00	0.00	0.00	0.00	—	0.00
Net Profit	-20	-6.44	-8.79	-11	-10	-10	-6.01	-0.66	—	-1.30
EPS in Rs	—	—	—	-1.45	-1.37	-1.37	-0.78	-0.10	-0.08	-0.25
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	76	76	76	76	76	76	76	76	76	—
Reserves	99	-17	-23	-32	-43	-54	-58	-64	-65	—
Borrowings	15	15	9.85	9.13	10	11	12	13	14	0.00
Other Liabilities	123	124	124	124	124	123	118	118	118	0.00
Total Liabilities	313	198	187	177	167	157	147	142	142	—
Fixed Assets	141	61	51	41	31	21	11	6.45	6.36	0.00
CWIP	0.29	2.04	1.87	1.87	1.87	1.87	1.87	1.87	1.87	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.10	0.10	0.00
Other Assets	172	135	134	134	134	134	134	134	134	0.00
Total Assets	313	198	187	177	167	157	147	142	142	—

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	6.47	0.02	-0.63	-1.74	0.14	0.01	0.10	0.00	0.00	1.20
Cash from Investing Activity	-6.47	-0.00	3.05	1.74	0.00	-0.03	-0.10	-0.01	0.00	-1.70
Cash from Financing Activity	-0.00	-0.00	-2.37	0.00	-0.20	0.00	0.00	0.00	0.00	0.78
Net Cash Flow	-0.00	0.02	0.05	-0.00	-0.06	-0.01	0.00	-0.01	0.00	0.28

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	23.64%	23.64%	23.64%	23.64%	23.64%	23.64%	23.64%	23.64%	23.64%	23.64%	23.64%	23.64%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	76.36%	76.36%	76.36%	76.36%	76.36%	76.36%	76.36%	76.36%	76.36%	76.36%	76.36%	76.36%
Total Shareholders	11,342	11,360	12,220	12,426	12,766	12,963	13,307	13,583	13,475	13,461	13,545	13,767

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Board Meeting

5 days ago

Board to approve FY2026 audited results on May 29

Transgene Biotek Ltd will hold a board meeting on 29 May 2026 to consider and approve the audited standalone and consolidated financial results for Q4 and the year ended March 31, 2026.

Board Meeting Results

5 days ago

Board meeting to approve FY2026 audited results

Transgene Biotek will hold a Board meeting on 29 May 2026 to consider and approve audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026.

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Transgene Biotek Ltd

Transgene Biotek Ltd (TRABI) is currently trading at 3.15 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Transgene Biotek Ltd, founded in 1990, is a pioneering biotechnology company in India, focusing on research and development of vaccines, oncology products, and new drug delivery technologies. The company has a robust product export portfolio, reaching markets in Africa, Russia, China, Malaysia, and the Philippines. A significant development includes the planned setup of a manufacturing facility at Anrich Industrial Area with a Rs. 30 crore investment, supported by preferential offer funding from Batterymarch Financial Management USA and other financial institutions. Transgene is advancing in novel delivery systems for proteins, peptides, and biologicals, with a particular emphasis on oral and nasal formulations. The company targets novel therapies in oncology and auto-immune diseases, addressing vital areas of unmet medical need.

Over the past 52 weeks, Transgene Biotek Ltd has traded between a low of ₹1.83 and a high of ₹5.26. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Transgene Biotek Ltd has a market capitalization of approximately 23.41. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Transgene Biotek Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -12.32 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 23.41 Cr, Transgene Biotek Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Transgene Biotek Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Transgene Biotek Ltd is -12.32. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Transgene Biotek Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Unlock more with professional

Projection

Documents

Actions

Announcements

Board to approve FY2026 audited results on May 29

Board meeting to approve FY2026 audited results

AI Mode

Ask AI

Frequently Asked Questions about Transgene Biotek Ltd

What is Transgene Biotek Ltd share price today?

What does Transgene Biotek Ltd do?

What is the 52-week high and low of Transgene Biotek Ltd?

What is the market capitalization of Transgene Biotek Ltd?

Should I consider investing in Transgene Biotek Ltd stock?

Is Transgene Biotek Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Transgene Biotek Ltd belong to and why does it matter?

What is the PE ratio of Transgene Biotek Ltd?

Investor’s Suite

Market Explorer

Market Pulse

Deep Dive

Utility

Company

Technicals

Documents

Frequently Asked Questions about Transgene Biotek Ltd

What is Transgene Biotek Ltd share price today?

What does Transgene Biotek Ltd do?

What is the 52-week high and low of Transgene Biotek Ltd?

What is the market capitalization of Transgene Biotek Ltd?

Should I consider investing in Transgene Biotek Ltd stock?

Is Transgene Biotek Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Transgene Biotek Ltd belong to and why does it matter?

What is the PE ratio of Transgene Biotek Ltd?

Projection

Announcements

Board to approve FY2026 audited results on May 29

Board meeting to approve FY2026 audited results

Oscillators

Neutral

Overall

Bullish

Moving Averages

Bullish

Overall

Bullish

Overview

Financial Ratios

Peers

Price Chart Comparison

Investment Checklist